Specac Acquires Amax, Forging a Global OEM Powerhouse

ORPINGTON, UK – January 21, 2026 – Specac, Ltd., a leader in spectroscopy accessories, today announced its acquisition of Amax Precision Ltd., a specialist in high-precision contract manufacturing for the analytical instrument sector. The move, orchestrated by Specac's parent company, private equity firm Ampersand Capital Partners, creates a formidable global original equipment manufacturer (OEM) partner with expanded technological capabilities and a significantly strengthened presence in the life sciences market.

The merger combines Specac's expertise in designing and manufacturing spectroscopy accessories with Amax's proficiency in producing critical, high-tolerance machined components. The resulting entity boasts a workforce of over 400 employees across facilities in the UK, USA, Singapore, Malaysia, and India, establishing a strategic manufacturing footprint on three continents.

A Strategic Play for Vertical Integration

This acquisition represents a calculated step towards creating a more vertically integrated and resilient business model. By bringing Amax's high-precision engineering and assembly capabilities in-house, Specac can now exercise greater control over its supply chain, from the foundational machined parts to the final, complex spectroscopic accessories. This integration is poised to deliver enhanced quality control, improved production efficiency, and a more secure supply of critical components for its OEM partners.

“This acquisition is a pivotal step in building a best-in-class OEM partner for analytical instrumentation,” said Mark Dearden, President and CEO of Specac Group. “We are delighted with the opportunity to support existing Specac and Amax customers with an expanded set of capabilities as an OEM Partner.”

The move aligns perfectly with the investment strategy of Ampersand Capital Partners, a firm known for its "picks and shovels" approach in the healthcare sector. Ampersand focuses on acquiring and building companies that provide mission-critical tools and services to innovators, rather than investing directly in drug discovery. The firm acquired Specac in March 2024 and quickly followed with the acquisition of Harrick Scientific's assets, signaling a clear intent to consolidate and lead the spectroscopy accessory market. The addition of Amax is the next logical step in this build-up.

Dave Patteson, a Partner at Ampersand, commented on the strategic fit, stating, “Amax’s merger into the Specac group will substantially increase scale, client capabilities, and life science contributions. Specac and Amax have complementary and high-quality offerings, multi-decade client relationships, and strong technical leadership.”

Fusing Spectroscopy and Precision for Life Sciences

The technological synergy between the two companies is expected to be a primary driver of future growth, particularly within the booming life sciences sector. The global analytical instrumentation market, valued at approximately $55 billion in 2024, is projected to grow at a CAGR of nearly 6% over the next decade, with biopharmaceutical research, drug discovery, and diagnostics being major catalysts.

Amax Precision, founded in 1995, has built its reputation on manufacturing critical machined parts with ultra-low micron tolerances. This level of precision is non-negotiable in applications such as DNA sequencing, medical diagnostics, and surgical equipment—all key segments for Amax. Specac, in turn, designs the sophisticated infrared accessories, optics, and process cells that are integral to the analytical instruments used in these fields.

By combining these capabilities, the new group can accelerate innovation and shorten development cycles for next-generation products. The integrated R&D and manufacturing process allows for a seamless transition from accessory design to the production of its most intricate components. This is a significant advantage in a market that demands both rapid innovation and unwavering reliability. The fusion of Specac's deep application knowledge in spectroscopy with Amax's manufacturing prowess creates a powerful engine for developing advanced solutions tailored to the exacting standards of medical and life science researchers.

Building a Resilient Global Supply Chain

The acquisition dramatically expands the group's international presence, creating a global manufacturing and service network. Specac’s existing facilities in Orpington, UK, and Mt. Kisco, New York, are now complemented by Amax’s headquarters in Singapore and production sites in Melaka, Malaysia, and Coimbatore, India. This three-continent footprint is a major strategic asset.

This geographical diversification offers significant advantages for OEM clients. It provides enhanced supply chain resilience by mitigating risks associated with relying on a single region for manufacturing. Furthermore, it co-locates production and engineering resources closer to key customer hubs, particularly in the Asia-Pacific region, which is the fastest-growing market for analytical instruments. This proximity can lead to more responsive service, streamlined logistics, and a deeper understanding of regional market needs.

Thomas Chen, Chairman of Amax, highlighted the global opportunities presented by the merger. “Joining Specac marks an exciting new chapter,” he said. “This not only broadens our exposure to new global markets but also represents a meaningful new step for us. We appreciate the support that will help us grow and gradually reach the next level.”

For OEM partners, this translates into a more robust and simplified partnership. They can now source a wider range of integrated solutions from a single, globally-scaled supplier committed to quality and innovation. The combined entity is better positioned to manage complex international supply chains, ensuring a stable and reliable flow of mission-critical components to instrument manufacturers around the world. This strategic expansion solidifies the group's position not merely as a component supplier, but as a comprehensive solutions partner ready to meet the evolving demands of the global analytical science community.